Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

CALR mutation

PharmaDeviceNews CALR mutation

Representative image: Hematology researchers review blood analysis data as Incyte Corporation’s INCA033989 data highlight potential progress in CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Pharma & Biotech

Why Incyte INCA033989 could reshape essential thrombocythemia and myelofibrosis care

by Pallavi Madhiraju
June 14, 2026
0 Comments

Find out how Incyte INCA033989 data could reshape CALR-mutated myelofibrosis and essential thrombocythemia treatment.

Read More

Latest news and features

Six popular sunscreen ingredients face growing scrutiny. CS Analytical sees a testing opportunity
Eli Lilly is building a $3.5bn retatrutide factory. Why will patients wait until 2031?
Bracco’s new AI can flag brain aneurysms above 3 mm. Can it improve radiology detection?
HTL Biotechnology is betting €15m on salmon-derived DNA. Can regenerative medicine justify the expansion?
Novo Nordisk cut sickle cell crises by 27%. Could etavopivat become its next major medicine?
Why The Boots Group is selling Farmacias Benavides to Farmacias del Ahorro
AI can design protein binders in minutes. Sino Biological wants to validate them in three days
Molecular Designs has cleared its first FDA hurdle. Can its three-virus PCR panel compete on workflow?
Dana-Farber cut cfDNA library variability to 8%. Could this solve a major liquid biopsy bottleneck?
Innovent just secured seven reimbursement wins in China. Can mazdutide deliver its next growth surge?
Could routine OB/GYN visits become a frontline defence against heart disease? Unified is testing the idea
IMFINZI’s new bladder cancer regimen cut death risk by 42%. Can AstraZeneca win against an approved rival?

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

Trend Micro shares surge 8.3% as Vision One SaaS revenue momentum challenges falling profits
LangChain raises $300m at $3bn valuation as enterprise AI agents face governance test
Black Bayou begins $1.6bn Louisiana gas storage build as LNG demand accelerates
WeFetch AI completes Canadian corporate rename as gtinfetch expands product verification
LaserAway opens Willowbrook clinic, extending founder-led aesthetic dermatology network to 36 states

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.